PetVivo Holdings Reports 140% Revenue Growth but Incurred Net Loss in Latest Quarter

PetVivo Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated revenues of $297,500, a substantial increase from $123,751 in the same period last year, marking a 140% rise. This growth was attributed to the introduction of the Precise PRP product, which contributed $149,257 to the total revenue, alongside $148,243 from the company's flagship product, Spryng®. Despite the revenue increase, PetVivo recorded a net loss of $2,311,037, compared to a loss of $2,047,063 in the prior year, reflecting ongoing operational challenges.

The company's total operating expenses decreased to $2,031,043 from $2,155,189 year-over-year, primarily due to reductions in general and administrative expenses and research and development costs. General and administrative expenses fell to $1,068,818 from $1,233,261, while R&D expenses decreased to $340,513 from $387,515. The operational loss for the quarter was $1,844,317, a slight improvement from the previous year's loss of $2,044,432, indicating some progress in cost management.

In terms of strategic developments, PetVivo has made notable changes to its product offerings and partnerships. The company signed an exclusive licensing agreement with VetStem, Inc. in February 2025 to market and sell the Precise PRP product, which is expected to generate revenue in fiscal year 2026. Additionally, PetVivo has expanded its distribution network, although it has recently terminated its non-exclusive distribution agreements with MWI Veterinary Supply Co. and Covetrus North America LLC, which previously contributed to its revenue.

Operationally, PetVivo's current assets as of June 30, 2025, stood at $4,400,859, significantly bolstered by cash reserves of $3,303,844, compared to $227,689 at the end of the previous quarter. The company’s current liabilities were $3,117,433, leading to a working capital of $1,283,426. However, the company continues to face substantial doubt regarding its ability to continue as a going concern, as indicated by its accumulated deficit of $93,538,130. Management has acknowledged the need for additional capital to support ongoing operations and plans to raise funds through the sale of securities.

Looking ahead, PetVivo's management remains focused on executing its business plan, which includes further commercialization of Spryng® and the development of additional products. The company is optimistic about its ability to raise necessary funds, although it recognizes the inherent risks associated with market conditions and its operational performance. The outlook for the upcoming fiscal year remains cautious, with the company emphasizing the importance of achieving profitability and securing adequate financing to sustain its operations.